Skip to main content

Editas Medicine, Inc.

corporate_fare Company Profile

Editas Medicine, Inc.

EDIT·NASDAQ·Life Sciences·CIK 0001650664

We are a pioneering gene editing company focused on developing genomic medicines to treat serious diseases. Our core capability uses CRISPR (clustered, regularly interspaced, short palindromic repeats) technology to create molecules that efficiently and specifically edit DNA. We have developed a proprietary gene editing platform based on CRISPR technology, which includes CRISPR/Cas9 and CRISPR/Cas12a systems, along with engineered forms and foundational intellectual property for both. This platform allows us to create gene editing molecules for over 95% of the human genome. Our mission is to translate gene editing into differentiated, transformational medicines for previously untreatable diseases. We aim to be a leader in in vivo gene editing, delivering therapies that simplify usability for patients, minimize burdens on patients and healthcare systems, and are distinct from current standards of care, while also enabling a simple, scalable manufacturing process to reduce costs.

Editas Medicine, Inc. (NASDAQ:EDIT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for EDIT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for EDIT spans 10-Q, 8-K, 424B5, S-3MEF.

Recent high-impact activity:

  • Editas 10-Q: $190.2M Cash, Runway Into 2H 2028, Q3 Loss Narrows to $23.4M
  • Editas Q3 Loss Narrows to $23.4M; Cash Runway Extended Into 2H 2028
  • Editas Q3 Loss Narrower Than Expected at $23.4M vs $27.7M Estimate
  • Editas Medicine Cleared to Start First-in-Human Trial of EDIT-401 for Hyperlipidemia
  • Editas Wins Approval to Start First-In-Human Trial of Gene-Editing Therapy EDIT-401

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$40.52M
Net Income
-$160.06M
Diluted EPS
-$1.80
Op. Cash Flow
-$165.24M
Free Cash Flow
-$165.85M
Operating Income
-$160.01M
Cash & Equivalents
$146.65M
Total Debt
$58.6M
Debt / Equity
2.15×
Net Margin
-395.0%
Shares Outstanding
97.87M sh
Source: 10-K · filed 2026-03-09 · accession 0001650664-26-000017

Short Interest & Short Volume

17.60 days to cover

FINRA reported short interest of 38,720,295 shares in EDIT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 17.6 days to cover at its recent average daily volume. On November 20, 2026, 57.3% of EDIT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)38,720,295 shares as of October 30, 2026
Change vs prior period▲ 1.4%
Days to cover17.60 at avg daily volume of 2,199,477
Daily short volume (FINRA facilities)57.3% of 1,273,978 shares on November 20, 2026
5-day average short volume62.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for EDIT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-31.

1 recent capital raiseATM program2 shelf registrations

Public Offering Priced · Significant Share Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$1.66 +1.22% today
52-week range · as of 2026-11-09 $1.66 – $3.94
Market cap
$253.12M
Volume
2.7M (1.2× avg)
3-mo avg 2.2M
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EDIT - Latest Insights

EDIT
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.75
Real-time Price: $1.66 info
Change: -$1.09 (-40%) info
Market Cap: $253.117M info
EDIT
Nov 09, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $1.66 info
Change: -$0.950 (-36%) info
Market Cap: $253.117M info
EDIT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $2.61
Real-time Price: $1.66 info
Change: -$0.950 (-36%) info
Market Cap: $253.117M info
EDIT
Oct 08, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.80
Real-time Price: $1.66 info
Change: -$1.14 (-41%) info
Market Cap: $253.117M info
EDIT
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.73
Real-time Price: $1.66 info
Change: -$1.07 (-39%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 5:30 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.98
Real-time Price: $1.66 info
Change: -$1.32 (-44%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $1.66 info
Change: -$1.32 (-44%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 8:35 AM EDT
Filing Type: S-3MEF
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $1.66 info
Change: -$0.690 (-29%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 8:12 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.30
Real-time Price: $1.66 info
Change: -$0.640 (-28%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.66 info
Change: -$0.640 (-28%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 6:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.84
Real-time Price: $1.66 info
Change: -$1.18 (-42%) info
Market Cap: $253.117M info
EDIT
May 26, 2026, 6:01 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.84
Real-time Price: $1.66 info
Change: -$1.18 (-42%) info
Market Cap: $253.117M info
EDIT
May 14, 2026, 6:16 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.93
Real-time Price: $1.66 info
Change: -$1.27 (-43%) info
Market Cap: $253.117M info
EDIT
May 14, 2026, 6:09 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.93
Real-time Price: $1.66 info
Change: -$1.27 (-43%) info
Market Cap: $253.117M info
EDIT
May 05, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.66 info
Change: -$1.36 (-45%) info
Market Cap: $253.117M info
EDIT
May 05, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.93
Real-time Price: $1.66 info
Change: -$1.27 (-43%) info
Market Cap: $253.117M info
EDIT
Apr 28, 2026, 4:34 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $3.07
Real-time Price: $1.66 info
Change: -$1.41 (-46%) info
Market Cap: $253.117M info
EDIT
Mar 27, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.22
Real-time Price: $1.66 info
Change: -$0.560 (-25%) info
Market Cap: $253.117M info
EDIT
Mar 09, 2026, 4:50 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.31
Real-time Price: $1.66 info
Change: -$0.650 (-28%) info
Market Cap: $253.117M info
EDIT
Mar 09, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.01
Real-time Price: $1.66 info
Change: -$0.350 (-17%) info
Market Cap: $253.117M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets